Approved HCV Drugs
Approved HCV Drugs
FDA Approves Once-Daily Coformulation of AbbVie's Viekira Regimen
- Details
- Category: Approved HCV Drugs
- Published on Friday, 29 July 2016 00:00
- Written by HIVandHepatitis.com
The U.S. Food and Drug Administration (FDA) has approved a new once-daily coformulation of AbbVie's paritaprevir-based "3D" regimen for hepatitis C virus (HCV) genotype 1, to be sold as Viekira XR, the company announced this week. AbbVie also said that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion on a shorter 12-week course of treatment with Viekirax for HCV genotype 4 patients with liver cirrhosis.
FDA Approves Gilead's Epclusa Combo Pill for All Hepatitis C Genotypes
- Details
- Category: Approved HCV Drugs
- Published on Wednesday, 29 June 2016 00:00
- Written by Liz Highleyman
On June 28 the U.S. Food and Drug Administration (FDA) approved Gilead Sciences Epclusa, a new once-daily combination pill containing sofosbuvir and velpatasvir, for the treatment of adults with hepatitis C virus (HCV) genotypes 1 through 6 -- the first approved oral pangenotypic regimen. While it is more effective against more types of HCV, Epclusa will cost less than most earlier interferon-free direct-acting antiviral regimens.
FDA Approves Harvoni for Hepatitis C Patients with Advanced Liver Disease
- Details
- Category: Approved HCV Drugs
- Published on Wednesday, 17 February 2016 00:00
- Written by Gilead Sciences
The U.S. Food and Drug Administration (FDA) has approved an expanded indication for Gilead Sciences sofosbuvir/ledipasvir coformulation (Harvoni) plus ribavirin for genotype 1 chronic hepatitis patients with decompenated liver cirrhosis and for genotype 1 or 4 liver transplant recipients without cirrhosis or with compensated cirrhosis, the company announced this week.
EASL 2016: DAAs for Hepatitis C Achieve Excellent Outcomes in Real-World Settings
- Details
- Category: Approved HCV Drugs
- Published on Friday, 22 April 2016 00:00
- Written by Michael Carter
Hepatitis C therapy with direct acting antivirals (DAAs) is as effective in real-world settings as it was in clinical trials, according to U.S. research presented at the International Liver Congress in Barcelona last week. Investigators from the Department of Veteran Affairs (VA) analyzed outcomes in over 9000 patients treated with DAA combinations. Outcomes were excellent, with 2 combinations achieving cure rates of 93%, similar to those seen in randomized studies with strict eligibility criteria and close follow-up.
FDA Approves Daclatasvir + Sofosbuvir for Hard-to-Treat Hepatitis C Patients
- Details
- Category: Approved HCV Drugs
- Published on Friday, 12 February 2016 00:00
- Written by Bristol-Myers Squibb
The U.S. Food and Drug Administration (FDA) this month approved an expanded indication for Bristol-Myers Squibb's daclatasvir (Daklinza) and Gilead Sciences sofosbuvir (Sovaldi) for additional patient groups including people with HIV/HCV coinfection, patients with advanced liver cirrhosis, and liver transplant recipients.
More Articles...
- AASLD 2015: High Cure Rate for People Retreated After Failure of Short Course DAA Therapy
- AASLD 2015: HCV Triple Regimen Cures Rapid Responders in 3 Weeks
- AASLD 2015: Daclatasvir + Sofosbuvir with Ribavirin Cures 90% of Genotype 3 Hepatitis C Patients
- AASLD 2015: Daclatasvir + Sofosbuvir Works Well for Genotype 3 HCV Patients with Advanced Disease
Web Design and Development by